Outcomes for Asian patients with multiple myeloma receiving once- or twice-weekly carfilzomib-based therapy: a subgroup analysis of the randomized phase 3 ENDEAVOR and A.R.R.O.W. Trials

• Published in: International journal of hematology Vol. 110; no. 4; pp. 466 - 473
• Main Authors: Dimopoulos, Meletios A., Moreau, Philippe, Iida, Shinsuke, Huang, Shang-Yi, Takezako, Naoki, Chng, Wee Joo, Zahlten-Kumeli, Anita, Sersch, Martina A., Li, Julia, Huang, Mei, Lee, Jae Hoon
• Format: Journal Article
• Language: English
• Published: Tokyo Springer Japan 01.10.2019; Springer Nature B.V
• Subjects: Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Asian Continental Ancestry Group; Bortezomib; Bortezomib - administration & dosage; Clinical trials; ClinicalTrials.gov; Dexamethasone; Dexamethasone - administration & dosage; Drug Administration Schedule; Hematology; Humans; Inhibitor drugs; Medicine; Medicine & Public Health; Multiple myeloma; Multiple Myeloma - drug therapy; Multiple Myeloma - mortality; NCT01568866; NCT02412878; Oligopeptides - administration & dosage; Oligopeptides - adverse effects; Oncology; Original Article; Proteasome inhibitors; Proteasome Inhibitors - administration & dosage; Proteasome Inhibitors - adverse effects; Randomization; Risk Assessment; Slopes; Subgroups; Survival; Survival Rate; Targeted cancer therapy; Treatment Outcome; Carfilzomib; Clinical trials; Relapsed and/or refractory multiple myeloma; Asian population

Carfilzomib is an irreversible proteasome inhibitor used for the treatment of relapsed and/or refractory multiple myeloma (RRMM). We evaluated the efficacy and safety of carfilzomib in subgroups of Asian patients in the randomized phase 3 ENDEAVOR and A.R.R.O.W. trials. In ENDEAVOR, patients receive...